Starting in 1999, GSK allegedly misrepresented to the Food and Drug Administration Avandia’s benefit of reducing diabetic cardiovascular risks and touted the drug as a better alternative for lowering blood sugars than other competing drugs. However, the lawsuit cites various studies, including one published in the New England Journal of Medicine, that found Avandia significantly increased diabetics’ risk of heart attacks and other serious cardiovascular events compared to other competing drugs.
Avandia was recently removed by regulators from the European market, and the FDA has recently restricted its use in the U.S.
Read the news release about Utah’s lawsuit against GlaxoSmithKline.
Read other coverage about GlaxoSmithKline:
– GlaxoSmithKline Execs May Face Prosecution Following Settlement
– GlaxoSmithKline Will Pay $750M to Settle Medicaid Fraud Lawsuit
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
